Vasomune completes enrollment for Pegevongitide study with FDA Fast Track designation

Vasomune Therapeutics completed patient enrollment in its Phase 2a clinical study (AV001-004) for Pegevongitide, a drug designed to target vascular responses in pneumonia. Pegevongitide already holds Fast Track designation from the U.S. Food and Drug Administration for the prevention and treatment of moderate-to-severe acute respiratory distress syndrome associated with respiratory infection. The company is now focusing on data quality assurance and preparation for database lock.

The completion of enrollment advances the program toward data review and analysis. The Fast Track designation from the U.S. Food and Drug Administration is intended to facilitate the development and review of therapies for serious conditions with unmet medical needs.